Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (15961)	8/13/2002 5:49:49 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

"" According to you, a third party created a clinical problem for Raptiva,"" When the data is submitted we will see what the facts are regarding rebound, and or flaring. Early on BGEN stressed Amevive has no rebound or flaring. Why not? This was discovered later. BGEN had a very narrow definition of rebound. The psoriasis had to be worse than baseline to be considered rebound. When one stops using Raptiva ones psoriasis returns. With the vast majority having reached 75% clearance, when one stops taking Raptiva, a return to a life with psoriasis is bound to be disappointing. But Raptiva will not be sold as a cure for psoriasis, nor will Amevive. Again, I impressed with your ability to fawn over BGEN management. Just like some Elan holders no matter what anyone says they knee jerk their support. As you know I asked other shareholders to vote against Xoma management at this years annual meeting.